BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Machado FHF, Castro Filho HF, Babadopulos RFAL, Rocha HAL, Rocha JLC, Moraes Filho MO. Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass1. Acta Cir Bras 2019;34:e20190010000009. [PMID: 30785510 DOI: 10.1590/s0102-865020190010000009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Salman MA, Salman A, Mohamed US, Hussein AM, Ameen MA, Omar HSE, Elewa A, Hamdy A, Elias AA, Tourky M, Helal A, Mahmoud AA, Aljarad F, Moustafa A, Shaaban HE, Nashaat A, Hussein AM, Omar T, Balamoun H. Ursodeoxycholic acid for the prevention of gall stones after laparoscopic sleeve gastrectomy: a prospective controlled study. Surg Endosc 2022. [PMID: 35020052 DOI: 10.1007/s00464-021-08980-3] [Reference Citation Analysis]
2 Choi JH, Lee SH, Cho IR, Paik WH, Ryu JK, Kim YT. Ursodeoxycholic acid for the prevention of gallstone and subsequent cholecystectomy following gastric surgery: A systematic review and meta-analysis. J Hepatobiliary Pancreat Sci 2021;28:409-18. [PMID: 33768730 DOI: 10.1002/jhbp.946] [Reference Citation Analysis]
3 Sneineh MA, Harel L, Elnasasra A, Razin H, Rotmensh A, Moscovici S, Kais H, Shirin H. Increased Incidence of Symptomatic Cholelithiasis After Bariatric Roux-En-Y Gastric Bypass and Previous Bariatric Surgery: a Single Center Experience. Obes Surg 2020;30:846-50. [PMID: 31901127 DOI: 10.1007/s11695-019-04366-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
4 Sakran N, Dar R, Assalia A, Neeman Z, Farraj M, Sherf-Dagan S, Gralnek IM, Hazzan R, Mokary SE, Nevo-Aboody H, Dola T, Kaplan U, Hershko D. The use of Ursolit for gallstone prophylaxis following bariatric surgery: a randomized-controlled trial. Updates Surg 2020;72:1125-33. [PMID: 32666477 DOI: 10.1007/s13304-020-00850-2] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Haal S, Guman MSS, Bruin S, Schouten R, van Veen RN, Fockens P, Dijkgraaf MGW, Hutten BA, Gerdes VEA, Voermans RP. Risk Factors for Symptomatic Gallstone Disease and Gallstone Formation After Bariatric Surgery. Obes Surg 2022. [PMID: 35143012 DOI: 10.1007/s11695-022-05947-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cheng Q, Hort A, Yoon P, Loi K. Review of the Endoscopic, Surgical and Radiological Techniques of Treating Choledocholithiasis in Bariatric Roux-en-Y Gastric Bypass Patients and Proposed Management Algorithm. Obes Surg 2021. [PMID: 34350533 DOI: 10.1007/s11695-021-05627-z] [Reference Citation Analysis]
7 Smirnov AV, Ivanov YV, Stankevich VR, Sharobaro VI, Velichko EA. Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery. Journal of Clinical Practice 2021;12:54-9. [DOI: 10.17816/clinpract71457] [Reference Citation Analysis]
8 Ying J, Dai S, Fu R, Hong J, Dai C, Jin Q. Effect of ursodeoxycholic acid on gallstone formation after bariatric surgery: An updated meta-analysis. Obesity (Silver Spring) 2022. [PMID: 35475596 DOI: 10.1002/oby.23427] [Reference Citation Analysis]
9 Akhmedov VA, Gaus OV. Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome. Medicinskij alfavit 2019;2:52-6. [DOI: 10.33667/2078-5631-2019-2-13(388)-52-56] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]